» Articles » PMID: 9353898

Comparison of Nicotinamide, Ethylurea and Polyethylene Glycol As Carriers for Nifedipine Solid Dispersion Systems

Overview
Specialties Chemistry
Pharmacology
Date 1997 Nov 14
PMID 9353898
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

The most prevalent means for producing solid dispersions of nifedipine, a poorly water-soluble drug, are the solvent based processes that bring problems of environmental and health. We have investigated the preparation of solid dispersions of nifedipine (mp 173 degrees C) by the fusion method, using nicotinamide, ethylurea, polyethylene glycol (PEG) 6000 and hydroxypropylmethylcellulose (HPMC) as carriers. All these solid dispersions were obtained by cooling at room temperature after heating at 140 degrees C for 15 min. As a single carrier, nicotinamide, ethylurea and PEG were used because nifedipine dissolved in their fused liquids. Compared with the physical mixtures, the solid dispersions with ethylurea or PEG led to a higher dissolution rate of the drug, whereas the difference in drug release between the physical mixtures and the solid dispersions with nicotinamide was not clear. This peculiarity might be due to the high solubilizing effect of nicotinamide for the drug. The fused mixtures of nicotinamide-, ethylurea- or PEG-HPMC were utilized as combined carriers. HPMC dissolved in the fused liquids of nicotinamide or ethylurea, which was effective in forming the amorphous nifedipine in solid dispersions. This resulted in not only the enhanced dissolution rate but also the supersaturation behavior of nifedipine. Further, for the nicotinamide-HPMC system, the supersaturation level of nifedipine increased with an increase in the HPMC content of solid dispersions. Nicotinamide was more applicable than ethylurea and PEG for preparation of the fused dispersions of nifedipine.

Citing Articles

Activity modelling of the solid-liquid equilibrium of deep eutectic solvents.

Kollau L, Vis M, van den Bruinhorst A, de With G, Tuinier R Pure Appl Chem. 2024; 91(8):1341-1349.

PMID: 39726941 PMC: 11670871. DOI: 10.1515/pac-2018-1014.


Development of Advanced 3D-Printed Solid Dosage Pediatric Formulations for HIV Treatment.

Malebari A, Kara A, Khayyat A, Mohammad K, Serrano D Pharmaceuticals (Basel). 2022; 15(4).

PMID: 35455431 PMC: 9025733. DOI: 10.3390/ph15040435.


Development of the Binary and Ternary Atorvastatin Solid Dispersions: and Investigations.

Faraji E, Mohammadi M, Mahboobian M Biomed Res Int. 2021; 2021:6644630.

PMID: 34527740 PMC: 8437629. DOI: 10.1155/2021/6644630.


Current pharmacological treatments for SARS-COV-2: A narrative review.

Nittari G, Pallotta G, Amenta F, Tayebati S Eur J Pharmacol. 2020; 882:173328.

PMID: 32603692 PMC: 7320862. DOI: 10.1016/j.ejphar.2020.173328.


Formulation of immediate release pellets containing famotidine solid dispersions.

Ibrahim M, El-Badry M Saudi Pharm J. 2014; 22(2):149-56.

PMID: 24648827 PMC: 3950527. DOI: 10.1016/j.jsps.2013.01.011.